| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,390,000 |
| Market
Cap: |
422.36(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.15 - $24.1 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,568 |
159,192 |
218,988 |
| Total Sell Value |
$0 |
$137,243 |
$3,016,052 |
$4,045,075 |
| Total People Sold |
0 |
2 |
9 |
9 |
| Total Sell Transactions |
0 |
2 |
17 |
25 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Astley-Sparke Philip |
Chief Executive Officer |
• • – |
2021-01-14 |
4 |
AS |
$43.06 |
$1,110,614 |
D/D |
(25,000) |
1,280,297 |
|
-17% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2021-01-14 |
4 |
AS |
$45.02 |
$900,400 |
D/D |
(20,000) |
175,994 |
|
-17% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2021-01-14 |
4 |
OE |
$1.01 |
$20,200 |
D/D |
20,000 |
195,994 |
|
- |
|
| Stampacchia Otello |
Director |
– • – |
2021-01-14 |
4 |
AS |
$45.09 |
$796,470 |
D/D |
(17,664) |
5,327,307 |
|
-17% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2021-01-14 |
4 |
AS |
$44.00 |
$663,465 |
D/D |
(14,900) |
0 |
|
-17% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2021-01-14 |
4 |
OE |
$14.08 |
$209,792 |
D/D |
14,900 |
14,900 |
|
- |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2021-01-13 |
4 |
AS |
$44.19 |
$4,419 |
D/D |
(100) |
0 |
|
-16% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2021-01-13 |
4 |
OE |
$14.08 |
$1,408 |
D/D |
100 |
100 |
|
- |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2020-12-23 |
4 |
OE |
$1.75 |
$88,732 |
D/D |
50,704 |
175,994 |
|
- |
|
| Coffin Robert |
President & Chief R&D Officer |
• • – |
2020-12-22 |
4 |
AS |
$40.04 |
$8,808,800 |
D/D |
(220,000) |
1,804,118 |
|
-17% |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-18 |
4 |
AS |
$41.95 |
$181,182 |
I/I |
(4,319) |
19,285 |
|
-8% |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-17 |
4 |
AS |
$42.00 |
$484,470 |
I/I |
(11,535) |
19,550 |
|
-12% |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-16 |
4 |
AS |
$42.13 |
$533,998 |
I/I |
(12,675) |
20,247 |
|
-15% |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-15 |
4 |
AS |
$42.40 |
$1,731,253 |
I/I |
(40,819) |
21,013 |
|
-22% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2020-12-14 |
4 |
AS |
$42.09 |
$1,086,200 |
D/D |
(25,000) |
0 |
|
-23% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2020-12-14 |
4 |
OE |
$14.08 |
$352,000 |
D/D |
25,000 |
25,000 |
|
- |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-14 |
4 |
AS |
$42.69 |
$1,637,847 |
I/I |
(37,659) |
23,481 |
|
-23% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2020-12-11 |
4 |
OE |
$3.30 |
$41,547 |
D/D |
12,590 |
125,290 |
|
- |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-11 |
4 |
AS |
$43.32 |
$1,372,512 |
I/I |
(31,636) |
25,757 |
|
-27% |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-10 |
4 |
AS |
$42.68 |
$1,484,083 |
I/I |
(34,391) |
27,669 |
|
-29% |
|
| Astley-Sparke Philip |
Chief Executive Officer |
• • – |
2020-12-10 |
4 |
AS |
$42.39 |
$1,076,145 |
D/D |
(25,000) |
1,305,297 |
|
-29% |
|
| Love Colin |
Chief Operating Officer |
• – – |
2020-12-09 |
4 |
AS |
$41.97 |
$1,312,382 |
D/D |
(30,000) |
976,524 |
|
-32% |
|
| Astley-Sparke Philip |
Chief Executive Officer |
• • – |
2020-12-09 |
4 |
AS |
$42.03 |
$1,093,729 |
D/D |
(25,000) |
1,330,297 |
|
-32% |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-09 |
4 |
AS |
$42.51 |
$1,804,182 |
I/I |
(41,216) |
29,748 |
|
-32% |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-08 |
4 |
AS |
$46.02 |
$5,056,591 |
I/I |
(108,256) |
32,234 |
|
-39% |
|
172 Records found
|
|
Page 5 of 7 |
|
|
0.13 (1.85%) 
